Phase Ib/II Study of Lacnotuzumab in Combination with Spartalizumab in Patients with Advanced Malignancies

Introduction: Blocking the colony-stimulating factor 1 (CSF-1) signal on tumor-associated macrophages can lead to an upregulation of checkpoint molecules, such as programmed cell death ligand 1 (PD-L1), thus causing resistance to this blockade. Combining spartalizumab (PDR001), a high-affinity, liga...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Jibran Ahmed, Bettzy Stephen, Yali Yang, Evan Kwiatkowski, Chinenye Lynette Ejezie, Shubham Pant
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Innovative Healthcare Institute 2024-05-01
Цуврал:	Journal of Immunotherapy and Precision Oncology
Нөхцлүүд:	lacnotuzumab spartalizumab pancreatic cancer melanoma endometrial cancer
Онлайн хандалт:	https://jipo.org/doi/pdf/10.36401/JIPO-23-16
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!